Loader

Pathways

PathWhiz ID Pathway Meta Data

PW109254

Pw109254 View Pathway
protein

Cadmium Induces DNA Synthesis and Proliferation in Macrophages

Bos taurus
Cadmium (Cd(2+)) exposure increases the risk of cancer in humans and animals. Humans may come into contact with cadmium when smoking and ingesting contaminated food. This will increase the risk of lung cancer and prostate cancer. In the millimolar range, cadmium will inhibit cell growth. Cadmium induces DNA synthesis and proliferation and affects signal transduction and mobilization in macrophages. At micromolar concentrations, cadmium significantly increased cell division as judged by thymidine uptake and cell counts. Activating this pathway will increase the availability of the transcription factor NF(kappa)B and will activate the early genes c-fos and c-myc.

PW109282

Pw109282 View Pathway
protein

Cadmium Induces DNA Synthesis and Proliferation in Macrophages

Rattus norvegicus
Cadmium (Cd(2+)) exposure increases the risk of cancer in humans and animals. Humans may come into contact with cadmium when smoking and ingesting contaminated food. This will increase the risk of lung cancer and prostate cancer. In the millimolar range, cadmium will inhibit cell growth. Cadmium induces DNA synthesis and proliferation and affects signal transduction and mobilization in macrophages. At micromolar concentrations, cadmium significantly increased cell division as judged by thymidine uptake and cell counts. Activating this pathway will increase the availability of the transcription factor NF(kappa)B and will activate the early genes c-fos and c-myc.

PW109207

Pw109207 View Pathway
protein

Cadmium Induces DNA Synthesis and Proliferation in Macrophages

Mus musculus
Cadmium (Cd(2+)) exposure increases the risk of cancer in humans and animals. Humans may come into contact with cadmium when smoking and ingesting contaminated food. This will increase the risk of lung cancer and prostate cancer. In the millimolar range, cadmium will inhibit cell growth. Cadmium induces DNA synthesis and proliferation and affects signal transduction and mobilization in macrophages. At micromolar concentrations, cadmium significantly increased cell division as judged by thymidine uptake and cell counts. Activating this pathway will increase the availability of the transcription factor NF(kappa)B and will activate the early genes c-fos and c-myc.

PW124249

Pw124249 View Pathway
metabolic

Cadena Transportadora y Fosforilación Oxidativa (CV)

Homo sapiens
Complejos transportadores de electrones (I, II, III y IV) para la generación de gradiente de protones en la mitocondria y fosforilación oxidativa para generar energía (ATP) mediante ATP sintasa.

PW124248

Pw124248 View Pathway
metabolic

Cadena transportadora de electrones y fosforilación oxidativa (CV) error

Homo sapiens
Complejos transportadores de electrones (I, II, III y IV) para la generación de gradiente de protones en la mitocondria y fosforilación oxidativa para generar energía (ATP) mediante ATP sintasa.

PW175987

Pw175987 View Pathway
metabolic

Cabozantinib Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Cabozantinib are predicted with biotransformer.

PW145863

Pw145863 View Pathway
drug action

Cabozantinib Drug Metabolism Action Pathway

Homo sapiens

PW128518

Pw128518 View Pathway
drug action

Cabozantinib Action Pathway

Homo sapiens
Cabozantinib is a tyrosine kinase inhibitor with broad applications in oncology. Originally approved in 2012 under the brand name Cometriq, it was primarily indicated for metastatic medullary thyroid cancer. Subsequently, a capsule formulation known as Cabometyx gained approval for the treatment of advanced renal cell carcinoma in 2016. In 2019, this same formulation received additional approvals for the treatment of hepatocellular carcinoma in patients who had previously been treated with sorafenib. Cabozantinib's mechanism of action involves inhibiting various receptor tyrosine kinases, effectively suppressing processes such as metastasis, angiogenesis, and oncogenesis, making it a versatile therapeutic option in the management of advanced cancers.

PW146443

Pw146443 View Pathway
drug action

Cabotegravir Drug Metabolism Action Pathway

Homo sapiens

PW127486

Pw127486 View Pathway
drug action

Cabotegravir Action Pathway

Homo sapiens
Cabotegravir is an HIV-1 integrase inhibitor used for treatment and pre-exposure prophylaxis of HIV-1 infection. It is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Cabotegravir is transported into the infected cell then transported into the nucleus via importin nuclear transporter. The viral RNA is injected into the cell then transcribed into viral DNA via reverse transcriptase. It is then transported into the nucleus where it is integrated into the host DNA. Cabotegravir inhibits HIV integrase which prevents the viral DNA from being integrated into the host DNA. This prevents viral replication and further progression of the virus. It is used in combination with reverse transcriptase inhibitors which further prevents viral replication and progression of the virus.